Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 14/20 | 0.49 |
| ▸ | MMP9 | P14780 | 13/20 | 0.49 |
| ▸ | MMP1 | P03956 | 13/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 10/20 | 0.49 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30506905 | 1.00 | MMP13 (0.49) | MMP13MMP9MMP1ADAM17IP6K1 | |
| SCHEMBL25315210 | 0.91 | MMP9 (0.50) | MMP13MMP9MMP1ADAM17IP6K1 | |
| SCHEMBL30507026 | 0.91 | MMP9 (0.50) | MMP13MMP9MMP1ADAM17IP6K1 | |
| SCHEMBL30507082 | 0.91 | MMP9 (0.47) | MMP13MMP9MMP1ADAM17IP6K1 | |
| SCHEMBL25317097 | 0.91 | MMP9 (0.47) | MMP13MMP9MMP1ADAM17IP6K1 | |
| SCHEMBL25321082 | 0.89 | MMP9 (0.45) | MMP13MMP9MMP1ADAM17IP6K1 | |
| SCHEMBL30506874 | 0.89 | MMP9 (0.45) | MMP13MMP9MMP1ADAM17IP6K1 | |
| SCHEMBL25318594 | 0.89 | IP6K1 (0.41) | MMP13MMP9MMP1ADAM17IP6K1 | |
| SCHEMBL30506975 | 0.89 | IP6K1 (0.41) | MMP13MMP9MMP1ADAM17IP6K1 | |
| SCHEMBL25318816 | 0.88 | MMP9 (0.43) | MMP13MMP9MMP1ADAM17IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | MMP13 835/4885MMP9 2139/4885MMP1 1137/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | MMP13 826/4885MMP9 2020/4885MMP1 1063/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | MMP13 835/4885MMP9 2139/4885MMP1 1137/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | MMP13 826/4885MMP9 2020/4885MMP1 1063/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | MMP13 826/4885MMP9 2020/4885MMP1 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.